Metronidazole

證據等級: L5

預測適應症: 10 個

Metronidazole: From Anaerobic/Protozoal Infections to Pneumocystosis

One-Sentence Summary

Metronidazole is a nitroimidazole antimicrobial internationally established for anaerobic bacterial and protozoal infections; specific South African regulatory indication text is not available in this evidence pack because the product currently has no SAHPRA registrations on record. The TxGNN model’s top-ranked prediction is Pneumocystosis (score 99.99%), but the 23 clinical trials and 10 publications returned show no direct evidence linking metronidazole to Pneumocystis treatment — this appears to be a knowledge-graph co-occurrence artifact rather than a genuine pharmacological signal.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack — no SAHPRA licenses on record
Predicted New Indication	Pneumocystosis
TxGNN Prediction Score	99.99%
Evidence Level	L4
South Africa Market Status	Not marketed (未上市)
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for metronidazole is not provided in this evidence pack. Based on well-established pharmacology, metronidazole is a nitroimidazole that is reduced intracellularly by anaerobic and microaerophilic organisms to generate cytotoxic free-radical intermediates that damage microbial DNA — this underlies its activity against anaerobic bacteria (e.g., Bacteroides, Clostridium) and protozoa (e.g., Entamoeba, Giardia, Trichomonas).

This mechanism does not provide a plausible link to Pneumocystis jirovecii, the causative organism of pneumocystosis, which is currently classified as a fungus rather than an anaerobic bacterium or protozoan. Metronidazole has no established antifungal or anti-Pneumocystis activity; the standard of care for pneumocystosis is trimethoprim-sulfamethoxazole (TMP-SMX), not nitroimidazoles.

Reviewing the supporting evidence confirms this gap: none of the 23 retrieved clinical trials investigate metronidazole for pneumocystosis, and the retrieved literature consists of general reviews of antiparasitic drugs or HIV-related opportunistic infections, plus incidental case reports where a patient received metronidazole for an unrelated condition (e.g., amebic dysentery) and separately developed pneumocystosis. The most likely explanation for the high TxGNN score is that metronidazole and pneumocystosis co-occur frequently in the same literature/knowledge-graph context (HIV/immunocompromised-host infections) without a genuine causal or therapeutic relationship.

Clinical Trial Evidence

No clinical trials directly evaluating metronidazole for pneumocystosis were identified. The broad search query returned 23 trials, but on review none investigate metronidazole treatment of pneumocystosis — the majority concern unrelated primary-care, opioid-management, diabetes-education, or care-delivery interventions. Representative examples, with their relevance grading, are shown for transparency:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02571673	N/A	Completed	65	Head-and-neck cancer survivorship tool feasibility study — not related to metronidazole or pneumocystosis
NCT03466866	Phase 3	Completed	156	Diabetes emergency-visit reduction education trial — not related; surfaced only via Phase 3 tag
NCT02208947	Phase 3	Terminated	77	Advance care planning financial-incentive trial — not related

Literature Evidence

None of the retrieved publications directly evaluate metronidazole as a treatment for pneumocystosis. Most are general antiparasitic-drug reviews or incidental case reports where metronidazole was used for a different infection in a patient who also had (or later developed) pneumocystosis.

PMID	Year	Type	Journal	Key Findings
1782741	1991	Review (pharmacokinetics)	Clinical Pharmacokinetics	General review of antiprotozoal drug regimens; does not address metronidazole for PCP
26518395	2015	Review	Topics in Antiviral Medicine	General review of HIV-related opportunistic infections; TMP-SMX (not metronidazole) is standard PCP therapy
2996829	1985	Review	Clinical Pharmacy	Reviews AIDS-related infectious complications; metronidazole not discussed as PCP therapy
6282154	1982	Case report	American Review of Respiratory Disease	Patient received metronidazole for diarrheal illness and separately developed PCP/CMV pneumonia — incidental co-occurrence, not treatment evidence
2338506	1990	Case report	Kansenshogaku Zasshi	Patient treated with metronidazole for amebic dysentery/liver abscess, later diagnosed with PCP on a separate admission — incidental co-occurrence
16496064	2005	Case report	J Formosan Medical Association	Colon perforation case involving CMV and amoebic colitis in an AIDS patient; metronidazole used for amoebiasis, not PCP
7355683	1980	Review	American Family Physician	Lists metronidazole for amebic colitis/trichomoniasis and TMP-SMX for PCP as separate drug-of-choice entries

South Africa Market Information

Currently no SAHPRA registrations are on record for this product (0 licenses; market status: not marketed). Regulatory indication and dosage form data cannot be extracted from this evidence pack.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (pneumocystosis) has no mechanistic plausibility — metronidazole has no known activity against Pneumocystis jirovecii, and none of the 23 clinical trials or 10 publications retrieved provide direct supporting evidence. This is assessed as a likely knowledge-graph co-occurrence artifact rather than a genuine repurposing signal (Evidence Level L4, Decision Stage S0).

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) covering warnings, contraindications, and DDI — this is a Blocking data gap (DG001) that must be resolved before any Stage 1 safety screening
Confirmed mechanism of action data (DG002, High severity) to properly evaluate any future repurposing candidates for this drug
If South African market entry is being considered independent of this prediction, formal SAHPRA registration status should be established

Note: This evidence pack contains 9 additional TxGNN-predicted indications for metronidazole. Two show notably stronger, mechanistically coherent evidence and warrant separate evaluation — cap polyposis (rank 9, evidence level L3, decision stage S2, recommendation “Proceed with Guardrails,” with direct literature discussing metronidazole’s anti-inflammatory mechanism in this condition) and ulceration of vulva (rank 10, evidence level L3, “Research Question,” supported by case-level evidence for cutaneous amebiasis and vulvar Crohn’s disease). These may be more productive candidates for further review than the top-ranked pneumocystosis signal.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.